NLG-0304: A phase 2B study of ipilimumab with or without dorgenmeltucel-L (HyperAcute-Melanoma) immunotherapy for patients with stage IV melanoma.
Adam I Riker
No relevant relationships to disclose
Gabriela R. Rossi
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Nicholas N. Vahanian
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Charles J. Link
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics